A Cost-Effectiveness Analysis of EGFR-TK Mutation Status-Guided 1st- and 2nd-Line Treatment of Stage III/IV Non-Small Cell Lung Cancer in the UK

Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2281
https://www.valueinhealthjournal.com/article/S1098-3015(14)04211-9/fulltext
Title : A Cost-Effectiveness Analysis of EGFR-TK Mutation Status-Guided 1st- and 2nd-Line Treatment of Stage III/IV Non-Small Cell Lung Cancer in the UK
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04211-9&doi=10.1016/j.jval.2014.08.2281
First page : A635
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 1735
Categories :
Tags :
Regions :
ViH Article Tags :